EHA Unplugged

European Hematology Association
  • 2.0 (1)
  • EDUCATION
  • UPDATED WEEKLY
EHA Unplugged

In these EHA-produced podcasts, experts share with you their hematology knowledge and stories. With "EHA Unplugged" we would like to give you the opportunity to unplug from your computer screen, while still learning, by listening to interviews, clinical cases, monologues, and more.

  1. Innovative Trial Design (EHA2024)

    6 DAYS AGO

    Innovative Trial Design (EHA2024)

    This podcast episode highlights the need to use innovative clinical trial designs in the era of increasingly personalized medicine in hematology. Listen to Dr Jurjen Versluis from Erasmus Medical Center in Rotterdam, the Netherlands, discuss his research on this topic. As the amount of novel targeted drugs is increasing, and treatments lead to increasingly better survival outcomes, we need to think about new, adaptive designs that will result in impactful trials in shorter time. Follow Dr Versluis as he explains the different designs and methods that can be used to estimate whether trial will be efficacious or futile before its completion. The combination of clinical trials with data from existing real-world registries, such as HARMONY or Dutch Cancer Society datasets, may also be an alternative to standard designs. By using examples of trials run by HOVON, the Dutch Hemato-oncology Foundation, Dr Versluis provides additional depth to the discussion.  Guest: Dr Jurjen Versluis This episode is part of a series of lectures recorded at the EHA congress in Madrid in June 2024. This podcast containing accompanying slide content is available as a video on Spotify, YouTube, and EHA Campus. More lectures will be available in the future. Stay tuned! For more information about a past or upcoming EHA Congress, visit https://ehaweb.org/congress/ Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f? Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe

    18 min
  2. Hereditary Hematological Malignancies (HHMs): A New Era of Discovery in MDS and AML (EHA2024)

    JAN 24

    Hereditary Hematological Malignancies (HHMs): A New Era of Discovery in MDS and AML (EHA2024)

    As knowledge about hereditary hematological malignancies (HHMs) increases, so do the options for better management of these diseases. Please join us in this podcast to hear Dr Kiran Tawana from Addenbrooke’s Hospital in Cambridge, UK, share her insights on this topic. HHMs are syndromes where two or more cases of cytopenia and hematological malignancy (typically MDS/AML) occur within the same family. Dr Tawana discusses the discovery of HHMs and provides advice on how to recognize them in clinical practice, which can be hampered by low penetrance and significant differences in disease latency. Listen to the stories of families affected by HHMs and how the molecular insights gathered from disease evolution in these case studies provide base for improved management of patients in the future. Tune in to hear the recommendations of dr. Tawana on how to optimize testing in clinical pathways and improve outcomes for people with HHMs. Guest: Dr Kiran Tawana This episode is part of a series of lectures recorded at the EHA congress in Madrid in June 2024. This podcast containing accompanying slide content is available as a video on Spotify, YouTube, and EHA Campus. More lectures will be available in the future. Stay tuned! For more information about a past or upcoming EHA Congress, visit https://ehaweb.org/congress/ Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. Provide Feedback Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe

    23 min
  3. Hairy Cell Leukemia (HCL): Treatment of Relapsed Disease (EHA2024)

    JAN 20

    Hairy Cell Leukemia (HCL): Treatment of Relapsed Disease (EHA2024)

    In this podcast, Prof Thorsten Zenz from University Hospital in Zurich, Switzerland, discusses the current approaches to treatment of relapsed hairy cell leukemia (HCL). Based on his personal journey as a hematologist interested in precision oncology, prof. Zenz summarizes the years of accumulating data and clinical experience to explain the treatment approach he often uses for his patients. Thanks to the clear molecular target (V600E mutation of BRAF), treatment of classical hairy cell leukemia with BRAF inhibitors, such as vemurafenib, is an example of precision oncology that can result in deep responses. As combination of this treatment with anti-CD20 antibody leads to durable complete responses in most patients, Prof Zenz often uses this regime in his patients with refractory or relapsed hairy cell leukemia. However, as different countries have access to different treatment options, Prof Zenz also discusses the role, sequencing and combinations of other drugs, such as to purine analogs (i.e. cladribine), MEK inhibitors, BTK-inhibitors, Bcl-2 inhibitors (i.e. venetoclax) or recombinant CD22-targeting immunotoxin (i.e. moxetumomab). In light of emerging (although still limited) data on these drugs and questions about their optimal sequencing, guidelines are being developed by Hairy Cell Leukemia Foundation (HCLF) and EHA that aim to help the clinicians with making choices for their patients. This podcast is further enriched by insights from prof. Enrico Tiacci from University and Hospital of Perugia in Italy, who discovered that V600E mutation of BRAF is the key genetic lesion underlying hairy cell leukemia. Prof Tiacci shares his views on the treatment options and their sequencing, based on the clinical trials he conducted and his clinical experience. Guest: Prof Thorsten Zenz This episode is part of a series of lectures recorded at the EHA congress in Madrid in June 2024. This podcast containing accompanying slide content is available as a video on Spotify, YouTube, and EHA Campus. More lectures will be available in the future. Stay tuned! For more information about a past or upcoming EHA Congress, visit https://ehaweb.org/congress/ Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. Provide Feedback Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe

    18 min
  4. Iron Metabolism in Myelodysplastic Syndrome (MDS)

    JAN 10

    Iron Metabolism in Myelodysplastic Syndrome (MDS)

    In this episode of EHA Unplugged, Prof Kirsten Grønbæk and our guests Prof Yelena Ginzburg and Prof Amit Verma discuss iron metabolism and its role in erythropoiesis in MDS. The experts share their views on the management of iron overload in the transfusion-dependent patients with MDS, as they acknowledge that it poses a real challenge in their clinical practice. Starting from the criteria used to select patients for iron chelation and then discussing its beneficial effects and limitations, the podcast guests formulate clear thoughts on the role of this therapy in both low- and high-risk MDS. They then clarify recent scientific insights into the putative mechanisms that may link iron overload with the ineffective erythropoiesis. Please tune in to hear about the data from a mouse model pointing to the role of iron transport in erythroblast function and differentiation (please also see the Reference). You will also hear what direction the future research into the mechanism of the communication between ineffective erythropoiesis and iron metabolism may take. This podcast is brought to you by EHA and the BioIron Society. Host: Prof Kirsten Grønbæk University of Copenhagen, Denmark Guests: Prof Yelena Ginzburg Icahn School of Medicine at Mount Sinai, NY, USA Prof Amit Verma Albert Einstein College of Medicine, NY, USA Reference: An W, et al. Iron chelation improves ineffective erythropoiesis and iron overload in myelodysplastic syndrome mice. Elife. 2023 Dec 28:12:e83103. doi: 10.7554/eLife.83103  Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. Provide Feedback Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe

    33 min
  5. First-line Treatment of Primary Central Nervous System Lymphoma (PCNSL) (EHA2024)

    12/27/2024

    First-line Treatment of Primary Central Nervous System Lymphoma (PCNSL) (EHA2024)

    In this podcast, Dr Elisabeth Schorb from University Medical Center in Freiburg, Germany, discusses the first-line treatment of primary central nervous system lymphoma (PCNSL), which has seen tremendous advances in the last years. PCNSL is a rare condition, and because of its location prompt diagnosis and timely treatment are of the essence. As for other hematological diseases, treatment of PCNSL today is based on two pillars: induction treatment and consolidation treatment. Listen to Dr Schrob describe her clinical experience and contributions to the international clinical trials that have shifted PCNSL prognosis from a disease with short life-expectancy if left untreated to a curable disease. And get inspired by Dr Schorb’s appeal to “stay tuned, stay in touch because your investigator-initiated ideas can make all the difference”.  Guest: Dr Elisabeth Schorb This episode is part of a series of lectures recorded at the EHA congress in Madrid in June 2024. This podcast containing accompanying slide content is available as a video on Spotify, YouTube, and EHA Campus. More lectures will be available in the future. Stay tuned! For more information about a past or upcoming EHA Congress, visit https://ehaweb.org/congress/ Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. Provide Feedback Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe

    18 min
  6. Optimizing Global Care for Women with von Willebrand Disease (VWD) (EHA2024)

    12/21/2024

    Optimizing Global Care for Women with von Willebrand Disease (VWD) (EHA2024)

    With the increasing scrutiny of healthcare pathways for women, this podcast provides a timely plea by Dr Michelle Lavin from St. James’s Hospital in Dublin, Ireland, to optimize global care for women with von Willebrand disease (VWD). In this podcast, Dr Lavin gives a passionate appeal for more international collaboration and increased awareness to improve care for women and girls suffering from bleeding disorders. As challenges facing women with these disorders are multiple, including diagnostic inequalities and suboptimal treatments, the solutions are also multi-factorial. Listen to dr. Lavin give her recommendations to provide the best possible care, based on the findings from the Annual Global Survey of the World Federation of Hemophilia, World Bleeding Disorder Registry and other data. In Dr Lavin’s own words: “there's momentum behind Women's Health”, so tune in to participate.  Guest: Dr Michelle Lavin This episode is part of a series of lectures recorded at the EHA congress in Madrid in June 2024. This podcast containing accompanying slide content is available as a video on Spotify, YouTube, and EHA Campus. More lectures will be available in the future. Stay tuned! For more information about a past or upcoming EHA Congress, visit https://ehaweb.org/congress/ Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. Provide Feedback Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe

    22 min
  7. Iron and Infections: Back to the Future (EHA2024)

    12/13/2024

    Iron and Infections: Back to the Future (EHA2024)

    In this lecture from EHA2024, Prof Domenico Girelli from University of Verona, Italy, discusses the complex relationship between iron metabolism and infection. As an essential element for physiology of all living organisms, iron is involved in many vital processes, including our immune responses to infections. Since the pathogens themselves also depend on iron to survive, the resulting host/pathogen “battle” for iron is one of the key determinants of outcomes of most infectious diseases. Interestingly, this dependence of pathogens on iron may offer a much-needed solution for multidrug resistance (MDR) of microbes, which poses a significant and growing challenge for the global healthcare. Tune in, to hear about the novel “metallo-antibiotics” and other clinical developments based on accumulating data about role of iron in infections.  Guest: Prof Domenico Girelli This episode is part of a series of lectures recorded at the EHA congress in Madrid in June 2024. This podcast containing accompanying slide content is available as a video on Spotify, YouTube, and EHA Campus. More lectures will be available in the future. Stay tuned! For more information about a past or upcoming EHA Congress, visit https://ehaweb.org/congress/ Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. Provide Feedback Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe

    18 min
  8. Long-term Outcomes in the Chemo-free era for Acute Promyelocytic Leukemia (EHA2024)

    12/06/2024

    Long-term Outcomes in the Chemo-free era for Acute Promyelocytic Leukemia (EHA2024)

    Join us for an insightful lecture by Prof Maria Teresa Voso from University of Rome Tor Vergata in Italy, as she discusses the advances in the treatment of a rare subtype of AML, the acute promyelocytic leukemia (APL). As the PML::RARA rearrangement, resulting in a fusion protein that disrupts retinoic acid signaling and PML function, is the hallmark driver of APL, it is used as target for APL treatment. Listen to Prof Voso as she talks about the scientific developments leading to significant improvements in clinical outcomes for patients with APL and the role of ATRA / ATO therapy, which combines all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). Prof Voso highlights contributions of the late prof. Francesco Lo Coco, the significance of the EU-wide HARMONY registry and other collaborative efforts in establishing the optimal treatment regimens for APL. This podcast also provides insights into remaining open issues in the clinical management of APL, including high-risk APL for which the results of the much-anticipated APOLLO trial may provide some answers.  This is part of a series of lectures recorded at the EHA congress in Madrid in June 2024. The podcasts in this series are better consumed in video form because of the accompanying slide content. More lectures will be available in the future. Stay tuned! For more information about a past or upcoming EHA Congress, visit https://ehaweb.org/congress/ Guest: Prof Maria Teresa Voso Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. Provide Feedback Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe

    19 min
See All (131)

About

In these EHA-produced podcasts, experts share with you their hematology knowledge and stories. With "EHA Unplugged" we would like to give you the opportunity to unplug from your computer screen, while still learning, by listening to interviews, clinical cases, monologues, and more.

Information

  • Creator
    European Hematology Association
  • Years Active
    2021 - 2025
  • Episodes
    131
  • Rating
    Clean
  • Copyright
    © Copyright 2024 - European Hematology Association All rights reserved.
  • Show Website
    EHA Unplugged

You Might Also Like

To listen to explicit episodes, sign in.

Stay up to date with this show

Sign in or sign up to follow shows, save episodes, and get the latest updates.
Select a country or region

Africa, Middle East, and India

Asia Pacific

Europe

Latin America and the Caribbean

The United States and Canada